Market Overview

Benzinga's Top Initiations

Related INFI
Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented at ASH 2014 Annual Meeting
Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma
Related CVD
5 Health Care Stocks Hurting From The Affordable Care Act
UPDATE: Credit Suisse Downgrades Covance Following Agreement To Be Acquired By LH

Analysts at William Blair initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ: INFI) with a “market perform” rating. The target price for Infinity Pharmaceuticals is set to $21. Infinity's shares closed at $19.20 yesterday.

Credit Suisse initiated coverage on shares of Covance (NYSE: CVD) with an “outperform” rating. The target price for Covance is set to $101. Covance's shares closed at $85.02 yesterday.

Jefferies initiated coverage on shares of Church & Dwight Co (NYSE: CHD) with a “buy” rating. The target price for Church & Dwight is set to $72. Church & Dwight's stock closed at $61.78 yesterday.

Analysts at Morgan Stanley initiated coverage on shares of Booz Allen Hamilton Holding (NYSE: BAH) with an “equal-weight” rating. The target price for Booz Allen Hamilton is set to $21. Booz Allen Hamilton's shares closed at $19.38 yesterday.

Latest Ratings for INFI

DateFirmActionFromTo
Dec 2014Credit SuisseUpgradesNeutralOutperform
Nov 2014NomuraMaintainsNeutral
Oct 2014Stifel NicolausInitiates Coverage onHold

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (CHD + BAH)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional